Evidence map›Paper›PMID 40707984›Full record

ArticleJournal of nanobiotechnology2025

Hypoxia-augmented chemotherapy potentiates imaging-guided combinatorial radionuclide-sonodynamic therapy for pancreatic cancer.

Jie An, Kaile Chu, Xirong Li, Huizhu Ma, Qin Zhou, Chenliang Niu, Jie Gao, Junping Lv, Jianbo Cao, XinYu Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jie An *Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Kaile Chu *Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Xirong Li *Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Huizhu MaDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Qin ZhouDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Chenliang NiuDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Jie GaoShanxi Key Laboratory of Drug Toxicology and Preclinical Studies for Radiopharmaceutical, CAEA Center of Excellence on Nuclear Technology Applications for Nonclinical Evaluation for Radiopharmaceutical, Taiyuan, 030006, Shanxi, People's Republic of China.
Junping LvDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Jianbo CaoDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
XinYu ZhangDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Haitao ZhouDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Hongliang WangDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Min LiDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China. limin7839@sxmu.edu.cn.
Zhifang WuDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China. wuzhifang01@163.com.
Sijin LiDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China. lisjnm123@163.com.

Funding

the National Natural Science Foundation of China 82102103
6 · The paper itself

Abstract

Radionuclide therapy and chemotherapy are effective for pancreatic cancer, yet their efficacy is often limited by tumor hypoxia. In this study, manganese porphyrin (MnTTP) and tirapazamine (TPZ) were encapsulated in polylactic-co-glycolic acid (PLGA) spheres, which were subsequently coated with polydopamine to label the radionuclide

Indexed as

Pancreatic NeoplasmsUltrasonic TherapyAnimalsCell Line, TumorCombined Modality TherapyHumansIndolesIodine RadioisotopesMagnetic Resonance ImagingMiceMice, Inbred BALB CMice, NudeNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerPolymersPorphyrinsIndolesIodine RadioisotopespolydopaminePolylactic Acid-Polyglycolic Acid CopolymerPolymersPorphyrinsReactive Oxygen SpeciesTirapazamineHypoxia-activated chemotherapyRadionuclide therapySonodynamic therapySPECT imagingSynergistic therapeutic

Identifiers

PMID40707984
PMCPMC12288203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.